2026 Specialty Measure Set

2026 MIPS Quality Measures for Oncology/Hematology

The 24 MIPS quality measures designated by CMS for the Oncology/Hematology specialty set. These are the measures oncology/hematology specialists are most likely to report on, though any MIPS-eligible measure can be submitted.

24measures
13high priority
22with benchmarks
12topped out
ID ↑Measure eCQMType Status
MIPS 047Advance Care Plan—High PriorityTopped Out
MIPS 102Prostate Cancer: Avoidance of Overuse of Bone Scan for Staging Low Risk Prostate Cancer PatientsCMS129v15High PriorityBenchmark
MIPS 130Documentation of Current Medications in the Medical RecordCMS68v15High PriorityTopped Out
MIPS 134Preventive Care and Screening: Screening for Depression and Follow-Up PlanCMS2v15ProcessTopped Out
MIPS 143Oncology: Medical and Radiation – Pain Intensity QuantifiedCMS157v14High PriorityTopped Out
MIPS 144Oncology: Medical and Radiation – Plan of Care for Pain—High PriorityTopped Out
MIPS 226Preventive Care and Screening: Tobacco Use: Screening and Cessation InterventionCMS138v14ProcessTopped Out
MIPS 238Use of High-Risk Medications in Older AdultsCMS156v14High PriorityTopped Out
MIPS 250Radical Prostatectomy Pathology Reporting—ProcessTopped Out
MIPS 317Preventive Care and Screening: Screening for High Blood Pressure and Follow-Up DocumentedCMS22v14ProcessTopped Out
MIPS 374Closing the Referral Loop: Receipt of Specialist ReportCMS50v14High PriorityTopped Out
MIPS 431Preventive Care and Screening: Unhealthy Alcohol Use: Screening & Brief Counseling—ProcessBenchmark
MIPS 450Appropriate Treatment for Patients with Stage I (T1c) - III HER2 Positive Breast Cancer—High PriorityTopped Out
MIPS 451RAS (KRAS and NRAS) Gene Mutation Testing Performed for Patients with Metastatic Colorectal Cancer who Receive Anti-epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody Therapy—ProcessBenchmark
MIPS 453Percentage of Patients who Died from Cancer Receiving Systemic Cancer-Directed—High PriorityBenchmark
MIPS 457Percentage of Patients who Died from Cancer Admitted to Hospice for Less than 3—High PriorityTopped Out
MIPS 490Appropriate Intervention of Immune-Related Diarrhea and/or Colitis in Patients Treated—ProcessBenchmark
MIPS 493Adult Immunization Status—ProcessBenchmark
MIPS 495Ambulatory Palliative Care Patients’ Experience of Feeling Heard and Understood—High PriorityBenchmark
MIPS 503Gains in Patient Activation Measure (PAM) Scores at 12 Months—High PriorityBenchmark
MIPS 506Positive PD-L1 Biomarker Expression Test Result Prior to First-Line Immune Checkpoint Inhibitor Therapy—High PriorityBenchmark
MIPS 507Appropriate Germline Testing for Ovarian Cancer Patients—ProcessBenchmark

All Specialty Sets

Need help selecting measures?

VBCA's clinical policy team helps practices choose the right measure mix based on patient population, benchmark opportunity, and program requirements.

Get a measure-mix review →